Creating a tool to help patients with acute myeloid leukemia make treatment decisions
Developing a Values Elicitation Tool to Improve Treatment Decision-Making in Acute Myeloid Leukemia
This study is creating a helpful tool called PRIME for people with acute myeloid leukemia (AML) to express what matters most to them in their treatment, so they can make better decisions with their doctors about their care.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11112298 on NIH RePORTER |
What this research studies
This research focuses on developing a tool called PRIME that helps patients with acute myeloid leukemia (AML) clarify their treatment preferences based on their personal values. By using a method called best-worst scaling, the tool generates a personalized report that assists patients and clinicians in shared decision-making. The goal is to improve the treatment decision-making process, especially as new therapies for AML become available. Patients will be engaged in discussions about what matters most to them, whether it's quality of life or survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acute myeloid leukemia who are facing treatment decisions.
Not a fit: Patients who are not diagnosed with acute myeloid leukemia or those who are not actively involved in treatment decision-making may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could empower patients with AML to make more informed treatment choices that align with their personal values.
How similar studies have performed: Previous research has shown promise in using values elicitation tools for patient decision-making, indicating that this approach could be effective.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Richardson, Daniel R — Univ of North Carolina Chapel Hill
- Study coordinator: Richardson, Daniel R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.